Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine in Major Depressive Disorder
NCT00411242Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (4 arms), sponsored by Novartis. Primary endpoint: Change from Baseline to Week 8 on the total score of the clinician rated 17-Item Hamilton Depression Rating Scale. Started Dec 2006; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00411242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411242.